Loss of YAP 1 defines neuroendocrine differentiation of lung tumors-Reference-Cited by-同舟云学术

Loss of YAP 1 defines neuroendocrine differentiation of lung tumors

Published:2016-09-09 Issue:10 Volume:107 Page:1527-1538
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Ito Takeshi¹,Matsubara Daisuke¹²,Tanaka Ichidai³,Makiya Kanae¹,Tanei Zen‐ichi¹,Kumagai Yuki¹,Shiu Shu‐Jen¹,Nakaoka Hiroki J.¹,Ishikawa Shumpei⁴,Isagawa Takayuki⁴,Morikawa Teppei⁵,Shinozaki‐Ushiku Aya⁵,Goto Yasushi⁶,Nakano Tomoyuki⁷,Tsuchiya Takehiro⁸,Tsubochi Hiroyoshi⁹,Komura Daisuke¹⁰,Aburatani Hiroyuki¹⁰,Dobashi Yoh¹¹,Nakajima Jun⁸,Endo Shunsuke⁷,Fukayama Masashi⁵,Sekido Yoshitaka³,Niki Toshiro²,Murakami Yoshinori¹

Affiliation:

1. Molecular Pathology Laboratory Institute of Medical Science University of Tokyo Tokyo Japan

2. Department of Integrative Pathology Jichi Medical University Tochigi Japan

3. Division of Molecular Oncology Aichi Cancer Center Research Institute Aichi Japan

4. Department of Genomic Pathology Medical Research Institute Tokyo Medical and Dental University Tokyo Japan

5. Department of Human Pathology Graduate School of Medicine University of Tokyo Tokyo Japan

6. Department of Respiratory Medicine Graduate School of Medicine University of Tokyo Tokyo Japan

7. Department of Thoracic Surgery Jichi Medical University Tochigi Japan

8. Department of Thoracic Surgery University of Tokyo Tokyo Japan

9. Department of Thoracic Surgery Jichi Medical University Saitama Medical Center Saitama Japan

10. Division of Genome Science Research Center for Advanced Science and Technology University of Tokyo Tokyo Japan

11. Department of Pathology Jichi Medical University Saitama Medical Center Saitama Japan

Funder

Japan Society for the Promotion of Science

Ministry of Health, Labour and Welfare

Smoking Research Foundation

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.13013

Reference33 articles.

1. Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-Up

2. Advances in neuroendocrine lung tumors

3. Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer

4. Prospective Study of Adjuvant Chemotherapy for Pulmonary Large Cell Neuroendocrine Carcinoma

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular subtype expression and genomic profiling differ between surgically resected pure and combined small cell lung carcinoma;Human Pathology;2023-11

2. POU2F3-Expressing Small Cell Lung Carcinoma and Large Cell Neuroendocrine Carcinoma Show Morphologic and Phenotypic Overlap;American Journal of Surgical Pathology;2023-10-31

3. Distinct microRNA Signature and Suppression of ZFP36L1 Define ASCL1-Positive Lung Adenocarcinoma;Molecular Cancer Research;2023-10-06

4. Tumor‐derived Vimentin as a novel biomarker for distinct subtypes predicting adjuvant chemotherapy resistance and T‐cell‐inflamed phenotype in small cell lung cancer;MedComm;2023-10

5. Molecular subtypes, predictive markers and prognosis in small-cell lung carcinoma;Journal of Clinical Pathology;2023-09-29